Ingelheim, Germany (ots/PRNewswire) – Boehringer Ingelheim announced today the initiation of a new phase III clinical trial to evaluate one of its two late-stage oncology pipeline compounds for the treatment of patients with advanced ovarian cancer. The clinical study, called LUME-Ovar-1 trial, investigates the compound BIBF 1120, a novel oral anti-angiogenic agent[1], for its efficacy [...]
Tag Archive > Novel Agents
European Commission Approval of New Indication for Roche’s Pegasys(R) (peginterferon alfa-2a) Offers Hepatitis C Patients a Second Chance for a Cure
Basel (ots/PRNewswire) – – Pegasys is the First and Only Pegylated Interferon to be Approved for Treatment of up to 72 Weeks in Treatment-Experienced Patients Roche announced today that the European Commission has approved Pegasys(R) (peginterferon alfa-2a (0 KD)) plus Copegus(R) (ribavirin) for the retreatment of hepatitis C patients who were not successfully treated with [...]
